Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab.
Share this article
Corporate
Score 45
Neutral
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab
Mar 29, 2026 20:50 UTC
JSPR, XLV, IJS
Short term
Related Articles
Score 85
Bullish
Palantir Technologies Just Banked a Blockbuster Week. 3 Important Developments Every Shareholder Should Know.
Mar 29, 22:22
Score 85
Bullish
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Mar 29, 20:54
Score 65
Bullish
How Datavault AI (DVLT) Reached Its First Profitable Quarter and Set a 2026 Growth Target
Mar 29, 20:53
Score 65
Bullish
Why Vertical Aerospace (EVTL) Is Expanding Its Valo Supplier Network Ahead of Certification
Mar 29, 20:52
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.